CL2013000098A1 - Composicion farmaceutica que contienen una formulacion activada y potenciada de un anticuerpo para el receptor canabinoide humano; metodos de uso. - Google Patents

Composicion farmaceutica que contienen una formulacion activada y potenciada de un anticuerpo para el receptor canabinoide humano; metodos de uso.

Info

Publication number: CL2013000098A1
Authority: CL; Chile
Prior art keywords: potentiated; antibody; formulation; activated; methods
Prior art date: 2010-07-15

Application number

CL2013000098A

Other languages

English (en)

Inventor

Oleg Lliich Epsthein

Alexandrovna Sergeeva Svetlana

Fyodorovna Dologovyh Liudmila

Anatolievna Kheyefets Irina

Leonidovna Dugina Julia

Alexandrovna Zabolotneva Julia

Alexandrovich Tarasov Sergey

Original Assignee

Epsthein Oleg Iliich

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-07-15

Filing date

2013-01-10

Publication date

2015-01-16

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44899164&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2013000098(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2010-07-15 Priority claimed from RU2010129289/15A external-priority patent/RU2552221C2/ru

2010-07-21 Priority claimed from RU2010130350/15A external-priority patent/RU2533224C2/ru

2011-06-02 Priority claimed from RU2011122407A external-priority patent/RU2610438C2/ru

2013-01-10 Application filed by Epsthein Oleg Iliich filed Critical Epsthein Oleg Iliich

2015-01-16 Publication of CL2013000098A1 publication Critical patent/CL2013000098A1/es

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0004—Homeopathy; Vitalisation; Resonance; Dynamisation, e.g. esoteric applications; Oxygenation of blood
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/06—Preparations for care of the skin for countering cellulitis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Immunology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Epidemiology (AREA)
Hematology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Alternative & Traditional Medicine (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Birds (AREA)
Dermatology (AREA)
Addiction (AREA)
Neurosurgery (AREA)
Microbiology (AREA)
Biomedical Technology (AREA)
Psychiatry (AREA)
Diabetes (AREA)
Mycology (AREA)
Obesity (AREA)
Neurology (AREA)
Child & Adolescent Psychology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

CL2013000098A 2010-07-15 2013-01-10 Composicion farmaceutica que contienen una formulacion activada y potenciada de un anticuerpo para el receptor canabinoide humano; metodos de uso. CL2013000098A1 (es)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
RU2010129289/15A RU2552221C2 (ru)	2010-07-15	2010-07-15	Способ лечения ожирения и сопутствующих метаболических расстройств и лекарственное средство для лечения ожирения и сопутствующих метаболических расстройств
RU2010130350/15A RU2533224C2 (ru)	2010-07-21	2010-07-21	Способ лечения зависимости от психоактивных веществ, алкоголизма и табакокурения и лекарственное средство для лечения зависимости от психоактивных веществ, алкоголизма и табакокурения
RU2011122407A RU2610438C2 (ru)	2011-06-02	2011-06-02	Способ лечения патологического синдрома и лекарственное средство центрального и периферического действия для лечения патологического синдрома

Publications (1)

Publication Number	Publication Date
CL2013000098A1 true CL2013000098A1 (es)	2015-01-16

Family

ID=44899164

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL2013000098A CL2013000098A1 (es)	2010-07-15	2013-01-10	Composicion farmaceutica que contienen una formulacion activada y potenciada de un anticuerpo para el receptor canabinoide humano; metodos de uso.

Country Status (30)

Country	Link
US (1)	US8865163B2 (es)
EP (1)	EP2593477A2 (es)
JP (1)	JP2013535436A (es)
KR (1)	KR20140012009A (es)
CN (1)	CN103124742A (es)
AR (1)	AR082246A1 (es)
AU (1)	AU2011278040B2 (es)
BR (1)	BR112013000841A2 (es)
CA (1)	CA2805091A1 (es)
CL (1)	CL2013000098A1 (es)
CZ (1)	CZ2013104A3 (es)
DE (1)	DE112011102349T5 (es)
DK (1)	DK201370078A (es)
EA (1)	EA029400B1 (es)
EE (1)	EE05760B1 (es)
ES (1)	ES2542042R1 (es)
FI (1)	FI20135146L (es)
FR (1)	FR2962653A1 (es)
GB (1)	GB2496076B (es)
IT (1)	ITTO20110641A1 (es)
LT (1)	LT5987B (es)
MX (1)	MX361778B (es)
MY (1)	MY158183A (es)
NO (1)	NO20130219A1 (es)
NZ (1)	NZ606768A (es)
PE (1)	PE20131338A1 (es)
PH (1)	PH12013500109A1 (es)
SE (1)	SE1350179A1 (es)
SG (1)	SG187037A1 (es)
WO (1)	WO2012007847A2 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RU2181297C2 (ru)	2000-06-20	2002-04-20	Эпштейн Олег Ильич	Способ лечения патологического синдрома и лекарственное средство
RU2309732C1 (ru) *	2006-03-13	2007-11-10	Олег Ильич Эпштейн	Спрессованная твердая оральная форма лекарственного препарата и способ получения твердой оральной формы лекарственного препарата
EP2593140A2 (en)	2010-07-15	2013-05-22	Oleg Iliich Epshtein	A method of increasing the effect of an activated-potentiated form of an antibody
JP2013538791A (ja) *	2010-07-15	2013-10-17	イリイチ・エプシテインオレグ	組み合わせ医薬組成物及び泌尿生殖器系障害を治療する方法
CA2804967A1 (en)	2010-07-15	2012-02-09	Oleg Iliich Epshtein	Combination pharmaceutical composition and methods of treating diseases or conditions associated with neurodegenerative diseases
ITTO20110632A1 (it)	2010-07-21	2012-01-22	Oleg Iliich Epshtein	Metodo per trattare il disturbo da deficit di attenzione e iperattivita'
CN103200964A (zh) *	2010-07-21	2013-07-10	奥列格·伊里奇·爱泼斯坦	复合药物组合物以及对与呼吸系统疾病或病症相关的疾病或病症进行治疗的方法
NZ606964A (en) *	2010-07-21	2015-08-28	Oleg Iliich Epshtein	A combination pharmaceutical composition and methods of treating diabetes and metabolic disorders
PE20131065A1 (es) *	2010-07-21	2013-09-23	Oleg Iliich Epshtein	Composiciones farmaceuticas combinadas y metodo de tratamiento del vertigo, la cinetosis y la distonia vegetativa-vascular
PH12013500232A1 (en) *	2010-08-06	2019-09-02	Oleg Iliich Epshtein	Combination pharmaceutical composition and methods of treating and preventing the infectious diseases
RU2013111962A (ru) *	2013-03-18	2014-09-27	Олег Ильич Эпштейн	Способ определения выраженности модифицирующей активности, ассоциированной с носителем
RU2013111961A (ru) *	2013-03-18	2014-09-27	Олег Ильич Эпштейн	Способ определения выраженности модифицирующей активности, ассоциированной с носителем
IL248006B2 (en) *	2014-03-27	2024-05-01	Bird Rock Bio Inc	Antibodies that bind to human cannabinoid receptor 1
CN104524568B (zh) *	2015-01-08	2018-04-20	中国人民解放军第二军医大学	一种治疗肥胖症的药物组合物及其应用
WO2017058771A1 (en) *	2015-09-30	2017-04-06	Bird Rock Bio, Inc.	Antibodies that bind human cannabinoid 1 (cb1) recetor
DK4021505T3 (da) *	2019-08-29	2024-02-12	Oleg Iliich Epshtein	Medikament til behandling af infektionssygdomme

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4311897A (en)	1979-08-28	1982-01-19	Union Carbide Corporation	Plasma arc torch and nozzle assembly
IL125743A (en)	1996-02-12	2003-09-17	Epshtein Oleg Iliich	Medicinal preparation containing an active medical substance with homeopathic potentiation
US5849528A (en)	1997-08-21	1998-12-15	Incyte Pharmaceuticals, Inc..	Polynucleotides encoding a human S100 protein
RU2156621C1 (ru)	1999-03-04	2000-09-27	Эпштейн Олег Ильич	Нейротропное лекарственное средство
RU2181297C2 (ru)	2000-06-20	2002-04-20	Эпштейн Олег Ильич	Способ лечения патологического синдрома и лекарственное средство
RU2209084C1 (ru) *	2001-12-26	2003-07-27	Эпштейн Олег Ильич	Лекарственное средство и способ лечения депрессивных расстройств
RU2201255C1 (ru)	2001-12-26	2003-03-27	Эпштейн Олег Ильич	Лекарственное средство и способ регуляции сосудистого тонуса
UA76640C2 (uk)	2002-08-02	2006-08-15	Олєг Ільіч Епштєйн	Спосіб корекції патологічних імунних реакцій та гомеопатичний лікарський засіб
UA76639C2 (uk)	2002-08-02	2006-08-15	Олєг Ільіч Епштєйн	Гомеопатичний лікарський засіб та спосіб лікування еректильних дисфункцій
UA76641C2 (uk)	2002-08-02	2006-08-15	Олєг Ільіч Епштєйн	Гомеопатичний лікарський засіб та спосіб лікування захворювань передміхурової залози
UA76638C2 (en)	2002-08-02	2006-08-15	Oleh Illich Epshtein	Homeopathic medication based on anti-interferon antibodies and method for treating a pathological syndrome associated with interferon
WO2004082597A2 (en)	2003-03-14	2004-09-30	Nutrition Research, Inc.	Homeopathic formulations useful for treating pain and/or inflammmation
US20050100513A1 (en)	2003-11-10	2005-05-12	Watkins Mary B.	Homeopathic method and system for treating nicotine addiction
EP1574211A1 (en) *	2004-03-09	2005-09-14	Inserm	Use of antagonists of the CB1 receptor for the manufacture of a composition useful for the treatment of hepatic diseases
RU2309732C1 (ru) *	2006-03-13	2007-11-10	Олег Ильич Эпштейн	Спрессованная твердая оральная форма лекарственного препарата и способ получения твердой оральной формы лекарственного препарата
RU2437678C2 (ru)	2006-06-06	2011-12-27	Олег Ильич Эпштейн	Лекарственное средство для перорального лечения ожирения и способ получения твердой лекарственной формы для пероральной терапии ожирения
EA200802440A1 (ru) *	2006-06-06	2009-06-30	Олег Ильич ЭПШТЕЙН	Лекарственное средство для лечения ожирения, сахарного диабета и заболеваний с нарушением толерантности к глюкозе
RU2438707C2 (ru)	2006-06-06	2012-01-10	Олег Ильич Эпштейн	Лекарственное средство для перорального лечения сахарного диабета и других заболеваний, сопровождающихся нарушением толерантности к глюкозе, и способ получения твердой лекарственной формы для пероральной терапии сахарного диабета и других заболеваний, сопровождающихся нарушением толерантности к глюкозе
TW200825067A (en)	2006-10-23	2008-06-16	Lilly Co Eli	CB1 compounds
EP1985295A1 (en)	2007-04-04	2008-10-29	Institut National De La Sante Et De La Recherche Medicale (Inserm)	Selective inhibitors of CB2 receptor expression and/or activity for the treatment of obesity and obesity-related disorders
JP2010132631A (ja) *	2008-11-04	2010-06-17	Bizen Chemical Co Ltd	カンナビノイド受容体のインバースアゴニストおよびアンタゴニスト活性を有する組成物
CA2804967A1 (en)	2010-07-15	2012-02-09	Oleg Iliich Epshtein	Combination pharmaceutical composition and methods of treating diseases or conditions associated with neurodegenerative diseases
EP2593138A2 (en)	2010-07-15	2013-05-22	Oleg Iliich Epshtein	Combination pharmaceutical composition and methods of treating functional diseases or conditions of gastrointestinal tract
NZ606964A (en)	2010-07-21	2015-08-28	Oleg Iliich Epshtein	A combination pharmaceutical composition and methods of treating diabetes and metabolic disorders
ITTO20110632A1 (it)	2010-07-21	2012-01-22	Oleg Iliich Epshtein	Metodo per trattare il disturbo da deficit di attenzione e iperattivita'
US20120258146A1 (en)	2010-07-21	2012-10-11	Oleg Iliich Epshtein	Method of treating organic diseases of nervous system, pschoorganic syndrome and encephalopathy
EP2596021A2 (en)	2010-07-21	2013-05-29	Oleg Iliich Epshtein	A method of treating alzheimer's disease
PE20131065A1 (es)	2010-07-21	2013-09-23	Oleg Iliich Epshtein	Composiciones farmaceuticas combinadas y metodo de tratamiento del vertigo, la cinetosis y la distonia vegetativa-vascular

2011
- 2011-07-15 MX MX2013000545A patent/MX361778B/es active IP Right Grant
- 2011-07-15 NZ NZ606768A patent/NZ606768A/en not_active IP Right Cessation
- 2011-07-15 GB GB1302653.9A patent/GB2496076B/en not_active Expired - Fee Related
- 2011-07-15 PE PE2013000073A patent/PE20131338A1/es not_active Application Discontinuation
- 2011-07-15 BR BR112013000841A patent/BR112013000841A2/pt not_active IP Right Cessation
- 2011-07-15 ES ES201390003A patent/ES2542042R1/es active Pending
- 2011-07-15 CZ CZ20130104A patent/CZ2013104A3/cs unknown
- 2011-07-15 PH PH1/2013/500109A patent/PH12013500109A1/en unknown
- 2011-07-15 CA CA2805091A patent/CA2805091A1/en not_active Abandoned
- 2011-07-15 SG SG2013002316A patent/SG187037A1/en unknown
- 2011-07-15 SE SE1350179A patent/SE1350179A1/sv unknown
- 2011-07-15 US US13/135,893 patent/US8865163B2/en not_active Expired - Fee Related
- 2011-07-15 CN CN2011800442270A patent/CN103124742A/zh active Pending
- 2011-07-15 DE DE112011102349T patent/DE112011102349T5/de not_active Ceased
- 2011-07-15 KR KR1020137003750A patent/KR20140012009A/ko not_active Application Discontinuation
- 2011-07-15 EA EA201300133A patent/EA029400B1/ru not_active IP Right Cessation
- 2011-07-15 IT IT000641A patent/ITTO20110641A1/it unknown
- 2011-07-15 JP JP2013519178A patent/JP2013535436A/ja active Pending
- 2011-07-15 WO PCT/IB2011/002404 patent/WO2012007847A2/en active Application Filing
- 2011-07-15 AU AU2011278040A patent/AU2011278040B2/en not_active Ceased
- 2011-07-15 EE EEP201300005A patent/EE05760B1/et not_active IP Right Cessation
- 2011-07-15 EP EP11788222.5A patent/EP2593477A2/en not_active Ceased
- 2011-07-15 MY MYPI2013000110A patent/MY158183A/en unknown
- 2011-07-15 FR FR1156473A patent/FR2962653A1/fr not_active Withdrawn
- 2011-07-18 AR ARP110102576A patent/AR082246A1/es unknown
2013
- 2013-01-10 CL CL2013000098A patent/CL2013000098A1/es unknown
- 2013-02-08 NO NO20130219A patent/NO20130219A1/no not_active Application Discontinuation
- 2013-02-14 LT LT2013015A patent/LT5987B/lt not_active IP Right Cessation
- 2013-02-14 DK DKPA201370078A patent/DK201370078A/da not_active Application Discontinuation
- 2013-02-15 FI FI20135146A patent/FI20135146L/fi not_active IP Right Cessation

Also Published As

Publication number	Publication date
CZ2013104A3 (cs)	2013-05-29
EE05760B1 (et)	2016-03-15
KR20140012009A (ko)	2014-01-29
WO2012007847A3 (en)	2012-04-12
GB2496076A (en)	2013-05-01
US20130017202A1 (en)	2013-01-17
ES2542042A2 (es)	2015-07-29
AU2011278040B2 (en)	2016-06-02
EA201300133A1 (ru)	2014-03-31
MX361778B (es)	2018-12-17
PE20131338A1 (es)	2013-11-18
CA2805091A1 (en)	2012-01-19
NO20130219A1 (no)	2013-03-22
GB2496076B (en)	2018-05-09
SG187037A1 (en)	2013-02-28
AR082246A1 (es)	2012-11-21
NZ606768A (en)	2015-08-28
PH12013500109A1 (en)	2015-07-03
DK201370078A (en)	2013-02-14
US8865163B2 (en)	2014-10-21
AU2011278040A1 (en)	2013-03-07
FI20135146L (fi)	2013-02-15
FR2962653A1 (fr)	2012-01-20
SE1350179A1 (sv)	2013-04-12
ITTO20110641A1 (it)	2012-01-16
WO2012007847A2 (en)	2012-01-19
LT5987B (lt)	2014-01-27
EE201300005A (et)	2013-08-15
ES2542042R1 (es)	2015-10-06
EP2593477A2 (en)	2013-05-22
LT2013015A (lt)	2013-11-25
JP2013535436A (ja)	2013-09-12
BR112013000841A2 (pt)	2016-06-07
CN103124742A (zh)	2013-05-29
DE112011102349T5 (de)	2013-04-18
MY158183A (en)	2016-09-15
MX2013000545A (es)	2013-10-28
GB201302653D0 (en)	2013-04-03
EA029400B1 (ru)	2018-03-30

Publication	Publication Date	Title
CL2013000098A1 (es)	2015-01-16	Composicion farmaceutica que contienen una formulacion activada y potenciada de un anticuerpo para el receptor canabinoide humano; metodos de uso.
BR112013003238A2 (pt)	2016-06-07	“sistema para preparar uma bebida, dispositivo de preparação de bebida, cápsula, kit, e, uso de uma cápsula”
BR112013011448A2 (pt)	2016-08-09	composto, composição farnmacêutica, e, uso do composto
BR112013018877A2 (pt)	2016-10-04	composições farmacêuticas que compreendem anticorpos humanos para pcsk9
CL2013000801A1 (es)	2013-11-29	Composicion farmaceutica que comprende un inhibidor de rankl y una hormona o un derivado de la misma, y uso del inhibidor rankl para preparar dicha composicion
BR112012013148A2 (pt)	2017-03-21	formulação farmacêutica e uso
BRPI0915928A2 (pt)	2015-11-03	composições e métodos de uso para anticorpos terapêuticos
BRPI0921699A2 (pt)	2016-02-16	complexo antioxidante, composicoes cosmeticas e farmaceutica contendo o referido complexo e uso deste complexo
CL2012002737A1 (es)	2013-02-15	Anticuerpo anti-cd40 humanizado; polinucleótido que lo codifica; composición farmacéutica que comprende dicho anticuerpo; y su uso para bloquear una respuesta inmunitaria mediada por cd40 humana.
CL2013003329A1 (es)	2014-07-04	Molécula de union a cd3 que comprende un dominio variable de cadena ligera (vl) y un dominio variable de cadena pesada (vh) capaz de unir un epitope de cd3 humano y de mamiferos no humanos; composición farmacéutica que comprende dicha molécula; y uso para preparar un medicamento.
CL2013001138A1 (es)	2014-11-14	Composicion que comprende anticuerpo biespecífico cd19xcd3 para tratar masa tumoral de tejido de ganglios linfáticos y/o linfoma extranodal causado por el linfoma b difuso de células grandes (lbdcg); kit farmacéutico; uso de la composición.
BRPI0809667A2 (pt)	2014-10-07	Composto, medicamento e composição farmacêutica que o contém e uso do composto
CR20120310A (es)	2012-08-01	Anticuerpos neutralizadores contra el receptor de prolactina y su uso terapéutico
CL2015000345A1 (es)	2015-05-22	Uso de una combinación para el melanoma que comprende la administración de cobimetinib y vemurafenib.
BR112012004335A2 (pt)	2015-09-08	composto, composição farmacêutica, e, uso do composto.
BRPI0917661A2 (pt)	2015-12-01	produto que contém macitentan, composição farmacêutica que o contém e uso de macitentan
BR112012031226A2 (pt)	2018-03-06	composto, uso do composto, composição farmacêutica, e uso de composição farmacêutica
IT1403847B1 (it)	2013-11-08	Composizioni farmaceutiche comprendenti rifaximina e loro uso.
BR112012012969A2 (pt)	2017-03-01	'' formulação farmacêutica líquida e uso de um antioxidante''
CR20130632A (es)	2014-02-04	El anticuerpo neutralizador del receptor de prolactina mat3 y su uso terapéutico
BR112013014189A8 (pt)	2018-01-09	composição farmacêutica, uso de um agente de potencialização e uso de uma composição
BRPI1009781A2 (pt)	2016-03-08	compostos para o tratamento de distúrbios metabólicos, composição farmacêutica que os compreende e uso dos mesmos
GT201200304A (es)	2014-06-09	Composiciones farmacéuticas que comprenden hidromorfona y naloxona
BRPI0916571A2 (pt)	2015-11-10	composto derivado de alquilaminometiloxazolidinona tricíclo, medicamento e composição farmacêutica que o contém e uso do composto
CL2014000267A1 (es)	2014-08-29	Formulacion farmaceutica liquida que comprende ketoprofeno, amitriptilina y oximetazolina; kit farmaceutico; metodo para prevenir o tratar la inflamacion.